VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
0.6300
+0.0054 (0.86%)
At close: Mar 20, 2026, 4:00 PM EDT
0.6219
-0.0081 (-1.29%)
After-hours: Mar 20, 2026, 7:50 PM EDT
VYNE Therapeutics Employees
VYNE Therapeutics had 10 employees as of December 31, 2025. The number of employees decreased by 3 or -23.08% compared to the previous year.
Employees
10
Change (1Y)
-3
Growth (1Y)
-23.08%
Revenue / Employee
$57,000
Profits / Employee
-$2,648,300
Market Cap
20.82M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | -3 | -23.08% | 10 | 0 |
| Dec 31, 2024 | 13 | 3 | 30.00% | 13 | 0 |
| Dec 31, 2023 | 10 | -2 | -16.67% | 10 | 0 |
| Dec 31, 2022 | 12 | -16 | -57.14% | 12 | 0 |
| Dec 31, 2021 | 28 | -78 | -73.58% | 28 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 25 |
| Daré Bioscience | 23 |
| Citius Pharmaceuticals | 23 |
| IN8bio | 17 |
| Skye Bioscience | 16 |
| FibroBiologics | 15 |
| NanoViricides | 7 |
| Lexaria Bioscience | 7 |
VYNE News
- 3 months ago - VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 7 months ago - VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 8 months ago - VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo - GlobeNewsWire
- 9 months ago - VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 - GlobeNewsWire
- 11 months ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 11 months ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga
- 11 months ago - VYNE Therapeutics Provides Update on VYN202 Program - GlobeNewsWire